Biointerface‐Engineered Hybrid Nanovesicles for Targeted Reprogramming of Tumor Microenvironment

Hybrid Biointerface EngineeringIn article number 2401495, Wei Tao, Sicen Wang, Xiaoyu Xie, and co‐workers present a novel biointerface‐engineered hybrid nanovesicle (P‐I@M1E/AAL), achieved by integrating M1‐like macrophage‐derived exosomes with AS1411 aptamer‐conjugated liposomes. The designed P‐I@M1E/AAL nanoplatform combines multiple treatment modalities, offering a promising therapeutic approach to overcome the challenges of the hypoxic and immunosuppressive tumor microenvironment. By reprogramming tumor‐associated macrophages and enhancing tumor‐targeted photodynamic‐immunotherapy, this platform shows significant potential for improving anti‐tumor treatment outcomes.